Articles

The Most Important Advances in Precision Medicine Being Presented at ASCO 2018

Dr David Spigel reviews 3 of the most important, practice-changing topics at ASCO 2018: new therapies targeting RET in a number of tumor types, a prognostic biomarker assay to predict whether patients with breast cancer will need adjuvant hormonal therapy or chemotherapy, and the minimum level of PD-L1 positivity required to predict outcomes with immunotherapy in lung cancer.

How Patient-Centric Care is Changing How Cancer Patients are Treated

By David Spigel, MD

Video, ASCO Highlights

Videos

Dr David Spigel considers how patient-reported outcomes, as well as palliative and supportive care, are revolutionizing cancer care so that consideration is being given to treating the patient, not just the cancer.

New Clinical Trial Data Presented at ASCO 2018: How Will it Change How you Practice?

By David Spigel, MD

Video, ASCO Highlights

Videos

Dr David Spigel discusses the 2 major themes highlighted at ASCO 2018: the use of cancer biomarkers to achieve precision therapy, and fine tuning treatment of patients with immunotherapy with respect to who to treat, how to treat, and how to predict clinical outcomes.

Explaining Treatment Regimens to Patients with HR+/HER2- Metastatic Breast Cancer

By Thomas Bachelot, MD, PhD

Breast Cancer, Video

Videos

Dr Thomas Bachelot is careful to set reasonable expectations for his patients with HR+/HER2- metastatic breast cancer regarding how long their treatment will last and how it will impact them.

HR+/HER2- Metastatic Breast Cancer: Common Presenting Symptoms

By Hope S. Rugo, MD

Breast Cancer, Video

Videos

Hope Rugo, MD, discusses common presenting symptoms of HR+/HER2- metastatic breast cancer, citing bone metastasis as the most prevalent.

An Overview of Existing and Emerging Biomarkers in Oncology

Faculty Perspectives: An Overview of Existing and Emerging Biomarkers in Oncology | Part 1 of a 4-Part Series

An increased understanding of the genomic and molecular underpinnings of cancer pathogenesis and their exploitation in the development of targeted therapies has revolutionized the treatment of many cancer types including BRAF-mutant melanoma, HER2-amplified breast cancer, and non–small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase rearrangements.

The Evolving Role of Biomarkers to Enhance Personalized Medicine

By Roy S. Herbst, MD, PhD

Faculty Perspectives: An Overview of Existing and Emerging Biomarkers in Oncology | Part 1 of a 4-Part Series

Biomarkers are critical for the personalization of therapy in oncology. It is quite clear that all therapies, no matter how potent, will require some personalization to reach their maximum effect.

Biomarkers and the Cancer Care Team: Critical Partners in Personalized Medicine

By Harris S. Goodman, MD

Faculty Perspectives: An Overview of Existing and Emerging Biomarkers in Oncology | Part 1 of a 4-Part Series

As discussed in the main article in this publication, the use of biomarkers has revolutionized the treatment of many types of cancer in a very personalized way, and has significantly affected the entire cancer care team, including (but not limited to) oncologists, oncology nurses, oncology nurse navigators, surgical and clinical pathologists, and pharmacists.

The Evolving Role of Biomarkers to Enhance Personalized Medicine

By Roy S. Herbst, MD, PhD

Faculty Perspectives - An Overview of Existing and Emerging Biomarkers in Oncology | Part 1 of a 4-Part Series

Biomarkers are critical for the personalization of therapy in oncology. It is quite clear that all therapies, no matter how potent, will require some personalization to reach their maximum effect.

Biomarkers and the Cancer Care Team: Critical Partners in Personalized Medicine

By Harris S. Goodman, MD

Faculty Perspectives - An Overview of Existing and Emerging Biomarkers in Oncology | Part 1 of a 4-Part Series

Articles

Page 104 of 289